Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1995;25(3):202–206. doi: 10.1007/BF00311527

Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis

Mitsuo Katano 1,✉, Mitsunari Nakamura 1, Tatsuya Matsuo 1, Akihiro Iyama 1, Takeharu Hisatsugu 1
PMCID: PMC7101795  PMID: 7543781

Abstract

In this study, the ability of granulocyte colony-stimulating factor (G-CSF) to treat or prevent chemotherapy-induced oral mucositis in patients with advanced breast cancer was evaluated. A total of 14 patients who received intra-arterial (i.a.) adriamycin (ADM) preoperatively were divided into two groups according to whether or not G-CSF was given. Thus, group A (n=7) was given G-CSF and group B (n=7) was not. G-CSF therapy reduced both the incidence and duration of ADM-induced oral mucositis, and a positive correlation was also seen between the incidence of mucositis and ADM-induced leukopenia (<2,000/mm3). Group A was further divided into two subgroups according to whether G-CSF was given after or before the leukopenia had dropped below 2,000/mm3: group A-1 (n=3) and group A-2 (n=4), respectively. ADM-induced mucositis was observed in two of the three patients in group A-1, but in none of the four patients in group A-2. These results strongly support the idea that G-CSF can effectively treat and prevent ADM-induced oral mucositis.

Key Words: oral mucositis, granulocyte colony-stimulating factor (G-CSF), adriamycin, chemotherapy

References

  • 1.Samueles BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep. 1987;71:971–972. [PubMed] [Google Scholar]
  • 2.Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407–1418. doi: 10.1200/JCO.1989.7.10.1407. [DOI] [PubMed] [Google Scholar]
  • 3.Hederson JC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989;7:560–571. doi: 10.1200/JCO.1989.7.5.560. [DOI] [PubMed] [Google Scholar]
  • 4.Gabizon A, Peretz T, Sulkes A, Amselem S, Ben-Yosef R, Ben-Baruch N, Catane R, Biran S, Berenholz Y. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol. 1989;25:1795–1803. doi: 10.1016/0277-5379(89)90350-7. [DOI] [PubMed] [Google Scholar]
  • 5.Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B, Benjamin RS. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989;63:37–45. doi: 10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  • 6.Mohood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneou TM, Sorensen JM, Gainey DK, Malliard JA, Gusa NL, Finck GK, Johnson C, Goldberg RM. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9:449–452. doi: 10.1200/JCO.1991.9.3.449. [DOI] [PubMed] [Google Scholar]
  • 7.Roth BJ, Sledge GW, Williams SD, Meyer SC, Ansari R, Fisher WB. Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. Cancer. 1991;68:248–252. doi: 10.1002/1097-0142(19910715)68:2<248::aid-cncr2820680205>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  • 8.Carmo-Perrira J, Costa FO, Miles DW, Henrigues E, Richards MA, Rubens RD. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma; a phase II study. Cancer Chemother Pharmacol. 1991;27:394–396. doi: 10.1007/BF00688864. [DOI] [PubMed] [Google Scholar]
  • 9.Reimann HA, deBerardinis CT. Periodic (cyclic) neutropenia, an entity. Blood. 1949;4:1109–1116. [PubMed] [Google Scholar]
  • 10.Hammond WP, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. New Engl J Med. 1989;320:1306–1311. doi: 10.1056/NEJM198905183202003. [DOI] [PubMed] [Google Scholar]
  • 11.Nicola NA, Metcalf D. Biochemical properties of differentiation factors for murine myelomonocytic leukemia cells in organ conditioned media-separation from colony-stimulating factor. J Cell Physiol. 1981;109:253–264. doi: 10.1002/jcp.1041090208. [DOI] [PubMed] [Google Scholar]
  • 12.Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Welte K. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232:61–65. doi: 10.1126/science.2420009. [DOI] [PubMed] [Google Scholar]
  • 13.Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton MK, Testa NG, Dexter TM. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809–813. doi: 10.1038/bjc.1987.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sherdan W, Metcalf D. Effect of granulocyte colonystimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988;1:667–672. doi: 10.1016/s0140-6736(88)91475-4. [DOI] [PubMed] [Google Scholar]
  • 15.Hanada T, Ono I. Disappearance of neutropenia oscillation in a child with cyclic neutropenia after treatment with recombinant human granulocyte colony-stimulating factor. Eur J Haematol. 1990;45:181–182. doi: 10.1111/j.1600-0609.1990.tb00451.x. [DOI] [PubMed] [Google Scholar]
  • 16.Freund MRF, Luft S, Shoeber C, Heussner P, Schrezenmaier H, Porzsolt F, Welte K. Differential effect on GM-CSF and G-CSF in cyclic neutropenia. Lancet. 1990;1:336. doi: 10.1016/0140-6736(90)91849-6. [DOI] [PubMed] [Google Scholar]
  • 17.Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. New Engl J Med. 1988;318:1414–1422. doi: 10.1056/NEJM198806023182202. [DOI] [PubMed] [Google Scholar]
  • 18.Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 19.Oheda M, Hase S, Ono M, Ikenaga T. Structure of the sugar chains of recombinant human granulocyte colony-stimulating factor produced by Chinese hamster ovary cells. J Biochem. 1988;103:544–546. doi: 10.1093/oxfordjournals.jbchem.a122305. [DOI] [PubMed] [Google Scholar]
  • 20.Asano S. Human granulocyte colony-stimulating factor: Its basic aspects and clinical applications. Am J Pediatr Hematol Oncol. 1991;13:400–413. doi: 10.1097/00043426-199124000-00004. [DOI] [PubMed] [Google Scholar]
  • 21.Sonis ST. Oral complications of cancer chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 2nd edn. Philadelphia: Lippincott; 1985. pp. 2014–2021. [Google Scholar]
  • 22.Yamamoto T, Yoneda K, Ueta E, Hirota J, Osaki T. Serum cytokine levels in patients with oral mucous membrane disorders. J Oral Pathol Med. 1991;20:275–279. doi: 10.1111/j.1600-0714.1991.tb00927.x. [DOI] [PubMed] [Google Scholar]
  • 23.Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WR, Whitmore WF. M-VAC (methotrexate, vinblastine, doxorubin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988;139:462–469. doi: 10.1016/s0022-5347(17)42494-3. [DOI] [PubMed] [Google Scholar]
  • 24.Wingard JR, Niehaus CS, Peterson DE, Jones RJ, Piantadosi S, Levin LS, Saral R, Santos GW. Oral mucositis after bone marrow transplantation: a marker of treatment toxicity and predictor of hepatic veno-occlusive disease. Oral Surg Oral Med Oral Pathol. 1991;72:419–424. doi: 10.1016/0030-4220(91)90552-n. [DOI] [PubMed] [Google Scholar]
  • 25.Kostmann R. Infantile genetic agranulocytosis (agranulocytosis infantilis hereditaria): a new recessive lethal disease in man. Acta Paediatr. 1956;105:1–78. [PubMed] [Google Scholar]
  • 26.Speat TH, Dameshe KW. Chronic hypoplastic neutropenia. Am J Med. 1952;13:35–45. doi: 10.1016/0002-9343(52)90079-x. [DOI] [PubMed] [Google Scholar]
  • 27.Platzer E, Welte K, Gabrilove J, Lu L, Harris P, Mertelsmann R, Moore MAS. Biological activities of human pluripotent hematopoietic colony-stimulating factor on normal and leukemic cells. J Exp Med. 1985;162:1788–1801. doi: 10.1084/jem.162.6.1788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Asano S, Ono M. Human granulocyte colony-stimulating factor: its biological actions and clinical implication. Acta Haematol Jpn. 1987;50:106–112. [PubMed] [Google Scholar]
  • 29.Kitagawa S, Yuo A, Souza LM, Saito M, Miura Y, Takaku F. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human glanulocytes stimulated by the chemotactic peptide. Biochem Biophys Res Commun. 1987;144:1143–1146. doi: 10.1016/0006-291x(87)91430-6. [DOI] [PubMed] [Google Scholar]
  • 30.Ohsaka A, Kitagawa S, Sakamoto S, Miura Y, Takanashi N, Takaku F, Saito M. In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma. Blood. 1989;74:2743–2748. [PubMed] [Google Scholar]

Articles from Surgery Today are provided here courtesy of Nature Publishing Group

RESOURCES